Indeed, treating highly aggressive MDA-MB-231 breast cancer cells with Paclitaxel promoted the secretion of EVs enriched with survivin that significantly contributed to the survival of serum-starved and Paclitaxel-treated fibroblasts and SKBR3 breast cancer cells [181]. This evidence concerns the gene BIRC5 and breast carcinoma.